Valuation: Genexine, Inc.

Market Cap 243B 172M 148M 139M 127M 238M 16.43B 242M 1.63B 639M 8.23B 645M 631M 27.34B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 174M 150M 141M 128M 241M 16.63B 245M 1.65B 647M 8.33B 653M 639M 27.67B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
25-09-30 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-09-22 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
25-03-07 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
24-09-30 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
24-07-04 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
24-06-25 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
24-05-14 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
23-11-14 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23-10-23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
23-08-31 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day-0.19%
1 week-0.76%
Current month+6.29%
1 month+11.49%
3 months-44.96%
6 months-40.72%
Current year-44.08%
1 week 2,590
Extreme 2590
2,810
1 month 2,220
Extreme 2220
2,810
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
12,300
5 years 2,140
Extreme 2140
71,846.15
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 2025-03-25
Chief Executive Officer 61 2023-01-26
Corporate Officer/Principal 49 2021-12-31
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 2022-03-28
Director/Board Member 61 2023-01-26
Date Insider Type Main position Quantity % Market Cap.
10/22/24 Others 156,632 0.3773%
10/22/24 Others

Chief Executive Officer

1,691,165 4.0741%
10/22/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-0.76%-47.28%-74.71% 84.3M
-1.90%+2.85%+62.82%+104.39% 70.07B
-3.21%-4.32%+31.85%+58.98% 52.87B
-2.05%-5.61%-3.18%+449.22% 27.02B
-1.27%-1.57%+45.90%+7.86% 23.61B
+1.05%-0.62%-18.00%-13.77% 23.38B
+3.81%+20.97%+266.37%+477.93% 19.43B
+0.10%+1.40%+35.36%-19.47% 18.75B
-0.95%-3.52%+19.93%+587.13% 15.85B
+1.24%-5.23%+33.75%+140.34% 12.7B
Average -0.34%+1.38%+42.75%+171.79% 26.38B
Weighted average by Cap. -1.09%+0.55%+50.20%+160.90%

Financials

2022 2023
Net sales 16.14B 11.42M 9.86M 9.27M 8.43M 15.84M 1.09B 16.11M 109M 42.45M 547M 42.87M 41.94M 1.82B 4.43B 3.13M 2.7M 2.54M 2.31M 4.35M 299M 4.42M 29.78M 11.64M 150M 11.76M 11.5M 498M
Net income -55.97B -39.6M -34.2M -32.14M -29.23M -54.95M -3.79B -55.86M -377M -147M -1.9B -149M -145M -6.3B -66.87B -47.31M -40.86M -38.4M -34.92M -65.65M -4.52B -66.73M -450M -176M -2.27B -178M -174M -7.53B
Net Debt 62.14B 43.96M 37.97M 35.68M 32.45M 61.01M 4.2B 62.01M 418M 163M 2.11B 165M 161M 7B 2.94B 2.08M 1.8M 1.69M 1.54M 2.89M 199M 2.94M 19.81M 7.75M 99.76M 7.82M 7.65M 332M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
26-08-14 ₩2,620.00 -0.19% 77,260
26-08-13 ₩2,625.00 -1.13% 87,397
26-08-12 ₩2,655.00 -3.63% 102,767
26-08-11 ₩2,755.00 +1.29% 124,438
26-08-10 ₩2,720.00 +3.03% 140,324
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock